bedaquiline and Myocardial-Infarction

A December 2019 WHO rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the health system. STREAM is the first randomised controlled trial with an economical evaluation to compare all-oral and injectable-containing 9-11-month MDR-TB treatment regimens.. Health system costs of delivering a 9-month injectable-containing regimen and a 9-month all-oral bedaquiline-containing regimen will be collected in Ethiopia, India, Moldova and Uganda, using 'bottom-up' and 'top-down' costing approaches. Patient costs will be collected using questionnaires that have been developed based on the STOP-TB questionnaire. The primary objective of the study is to estimate the cost utility of the two regimens, from a health system perspective. Secondary objectives include estimating the cost utility from a societal perspective as well as evaluating the cost-effectiveness of the regimens, using both health system and societal perspectives. The effect measure for the cost-utility analysis will be the quality-adjusted life years (QALY), while the effect measure for the cost-effectiveness analysis will be the efficacy outcome from the clinical trial.. The study has been evaluated and approved by the Ethics Advisory Group of the. ISRCTN18148631.

Topics: Antitubercular Agents; Cost-Benefit Analysis; Diarylquinolines; Ethiopia; Humans; India; Moldova; Myocardial Infarction; Rifampin; Tuberculosis, Multidrug-Resistant; Uganda

Topics: Antithrombins; Antitubercular Agents; Diarylquinolines; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Recombinant Proteins; Tuberculosis